S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
OTCMKTS:REVB

Revelation Biosciences - REVB Stock Forecast, Price & News

$0.20
0.00 (0.00%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.20
$0.22
50-Day Range
$0.20
$0.41
52-Week Range
$0.19
$11.29
Volume
223,367 shs
Average Volume
2.61 million shs
Market Capitalization
$4.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Revelation Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6,022.4% Upside
$12.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

REVB stock logo

About Revelation Biosciences (OTCMKTS:REVB) Stock

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

REVB Stock News Headlines

Revelation Biosciences Inc Unit (REVBU)
Revelation Biosciences, Inc. (REVB)
Revelation Biosciences GAAP EPS of -$0.12
Revelation Biosciences GAAP EPS of -$0.47
See More Headlines
Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

REVB Company Calendar

Last Earnings
11/10/2022
Today
12/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:REVB
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+6,022.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.30) per share

Miscellaneous

Free Float
18,852,000
Market Cap
$4.61 million
Optionable
Not Optionable
Beta
-0.35

Key Executives

  • Mr. James M. Rolke (Age 53)
    CEO & Director
    Comp: $466.63k
  • Mr. Chester Stanley Zygmont III (Age 42)
    Chief Financial Officer
    Comp: $366.64k
  • Ms. Sandra Vedrick
    VP of HR & Investor Relations
  • Ms. Carol Odle
    Sr. Director of Clinical Projects













REVB Stock - Frequently Asked Questions

Should I buy or sell Revelation Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revelation Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REVB shares.
View REVB analyst ratings
or view top-rated stocks.

What is Revelation Biosciences' stock price forecast for 2023?

1 Wall Street analysts have issued 1 year price targets for Revelation Biosciences' stock. Their REVB share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 6,022.4% from the stock's current price.
View analysts price targets for REVB
or view top-rated stocks among Wall Street analysts.

How have REVB shares performed in 2022?

Revelation Biosciences' stock was trading at $22.52 at the start of the year. Since then, REVB shares have decreased by 99.1% and is now trading at $0.1960.
View the best growth stocks for 2022 here
.

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (OTCMKTS:REVB) announced its quarterly earnings results on Thursday, November, 10th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03.

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revelation Biosciences investors own include Primo Water (PRMW), Almaden Minerals (AAU), AA (AATDF), American Assets Trust (AAT), Advance Auto Parts (AAP), AAON (AAON), Applied Optoelectronics (AAOI), Aaron's (AAN), American Airlines Group (AAL) and AAC Technologies (AACAY).

What is Revelation Biosciences' stock symbol?

Revelation Biosciences trades on the OTCMKTS under the ticker symbol "REVB."

Who are Revelation Biosciences' major shareholders?

Revelation Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.46%).
View institutional ownership trends
.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revelation Biosciences' stock price today?

One share of REVB stock can currently be purchased for approximately $0.20.

How much money does Revelation Biosciences make?

Revelation Biosciences (OTCMKTS:REVB) has a market capitalization of $4.61 million.

How can I contact Revelation Biosciences?

The official website for the company is www.revbiosciences.com. The company can be reached via phone at 971-622-5800 or via email at svedrick@revbiosciences.com.

This page (OTCMKTS:REVB) was last updated on 12/10/2022 by MarketBeat.com Staff